Peter Cackett

Abstract Objectives This report, based on guidance from a panel of UK retina specialists, introduces a revised intravitreal aflibercept (IVT-AFL) treat-and-extend (T&E) pathway for the treatment of neovascular age-related macular degeneration (nAMD). The T&E pathway incorporates the updated IVT-AFL label (April 2021) allowing flexible treatment intervals of 4 weeks to 16 weeks, after three initiation doses and a further dose after 8 weeks.

Dhillon et al. in their recent paper published in Eye proposed a redesign of elective cataract surgery in Scotland [1]. They stated that demand is expected to increase by 25% over the next 10 years as a result of our ageing population and they therefore described a new pathway to improve efficiency and reduce waiting times. Their study took place in 2018 prior to the Covid-19 pandemic.

This case report depicts the clinical course of a female patient with unilateral retinitis pigmentosa, who first presented at the age of 12 years. Fundus photography at the time revealed unilateral pigmentary retinopathy, which was associated with extinguished electroretinogram (ERG) signal. At 35 years of age, fundus examination revealed deterioration of pre-existing unilateral pigmentary retinopathy with progressive visual field defect detected on Goldmann visual field testing.